SM
ORMP icon

Sabby Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Sabby Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-972
Closed -$2.14M – 203
2021
Q3 		$2.14M Sell
972
-446
-31% -$7.6K 0.29% 49
2021
Q2 		$1.9M Sell
1,418
-268
-16% -$3.06K 0.27% 58
2021
Q1 		$1.71M Buy
1,686
+695
+70% +$5.7K 0.33% 57
2020
Q4 		$420K Buy
+991
New +$3.23K 0.08% 69
2020
Q3 		– Sell
-949
Closed -$335K – 145
2020
Q2 		$335K Sell
949
-860
-48% -$2.89K 0.07% 68
2020
Q1 		$550K Buy
1,809
+247
+16% +$1.08K 0.23% 38
2019
Q4 		$804K Buy
1,562
+1,427
+1,057% +$5.35K 0.22% 23
2019
Q3 		$43K Buy
+135
New +$450 0.02% 85

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sabby Management's ORMP Position: Q4 2021 in Review

Sabby Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 40,344 shares — an estimated $887K sold.

Sabby Management first reported a position in ORMP in Q2 2015 and held it in 8 quarters. The position peaked at $3.88M in Q3 2018. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

  • Sabby Management reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sabby Management sold 40,344 Oramed Pharmaceuticals shares in Q4 2021, an estimated $887K.
  • Sabby Management first reported a position in Oramed Pharmaceuticals in Q2 2015 and held it in 8 quarters.
  • Sabby Management's Oramed Pharmaceuticals position peaked at $3.88M in Q3 2018.
  • 116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.